Additional Information
Current position: MD-PhD Student, Medical Scientist Training Program, The Mayo Clinic
Lab legacy: Mouse gifs
TSBS publications:
- Treatment with novel topoisomerase inhibitors in Ewing sarcoma models reveals heterogeneity of tumor response. Lee U, Szabova L, Collins VJ, Gordon M, Johnson K, Householder D, Jorgensen S, Lu L, Bassel L, Elloumi F, Peer CJ, Nelson AE, Varriano S, Varma S, Roberts RD, Ohler ZW, Figg WD, Sharan SK, Pommier Y, Heske CM. Front Cell Dev Biol. 2024.
- Enhancing standard of care chemotherapy efficacy using DNA-dependent protein kinase (DNA-PK) inhibition in preclinical models of Ewing sarcoma. Collins VJ, Ludwig KR, Nelson AE, Sundara Rajan S, Yeung C, Vulikh K, Isanogle KA, Mendoza A, Difilippantonio S, Karim BO, Caplen NJ, Heske CM. Mol Can Ther. 2024.
- Inhibition of NAD+-dependent metabolic processes induces cellular necrosis and tumor regression in rhabdomyosarcoma models. McKay-Corkum GB, Collins VJ, Yeung C, Ito T, Issaq SH, Holland D, Vulikh K, Zhang Y, Lee U, Lei H, Mendoza A, Shern JF, Yohe ME, Yamamoto K, Wilson K, Ji J, Karim BO, Thomas CJ, Krishna MC, Neckers LM, Heske CM. Clin Cancer Res. 2023.
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma. Gibson AE, Yeung C, Issaq SH, Collins V, Gouzoulis M, Zhang Y, Ji J, Mendoza A, Heske CM. Oncogenesis. 2020.